Compare Summit Therapeutics Inc (SMMT) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? Summit Therapeutics Inc trades at $14.58 (market cap $10.48B), while Consumer Staples Select Sector SPDR Fund trades at $84.01. The key difference: Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | XLP | |
|---|---|---|
Market Cap | $10.48B | — |
Sector | Health | — |
52-Week High | $29.32 | $90.00 |
52-Week Low | $13.05 | $75.61 |
Enterprise Value | $9.90B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
XLP trades at $84.86, down 0.39% with a bullish technical signal from moving averages. The ETF shows strong analyst support with a 100% buy rating from 2 analysts and a 2.6% dividend yield. Recent news highlights XLP's defensive positioning amid market volatility, with consumer staples gaining favor as investors seek stability.
The outlook remains positive given XLP's defensive sector exposure and strong technical momentum. Key risks include sector concentration and macroeconomic pressures on consumer spending. With unanimous analyst bullishness and technical indicators supporting further upside, XLP presents a stable equity opportunity in uncertain markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
